Advisory Committee Chair
Candace L Floyd
Advisory Committee Members
Stephen A Watts
Jerzy P Szaflarski
Document Type
Thesis
Date of Award
2017
Degree Name by School
Master of Science (MS) College of Arts and Sciences
Abstract
In the United States, 2.5 million people experience a traumatic brain injury (TBI) every year and an estimated 5.3 million are living with a TBI-related disability. A TBI alters the function of the brain and the brain pathology often resulting in long-lasting cognitive impairment, motor function impairments, and emotional changes. In conjunction with the physical changes a victim of TBI experiences, the injury can take a financial toll. It is estimated that 76.3 billion dollars is attributed to the direct and indirect costs of sustaining a TBI every year in the United States. Despite improvements in managing TBI, there are currently no neuroprotective drugs available. This thesis is composed of a study to evaluate Perampanel (PRM), also known as Fycompa ®, and its potential as a neuroprotective agent in TBI. PRM is a selective noncompetitive AMPA receptor antagonist and is approved as an antiepileptic in the United States and Europe. This thesis investigates the effects of Perampanel on subacute biomarkers of neuroprotection in relation to cognitive deficits. Such parameters include learning and memory, anxiety, and reward-seeking/motivation implications. Keywords: traumatic brain injury-Perampanel-Fycompa-neuroprotection-AMPA receptor-AMPA receptor antagonist
Recommended Citation
Aida, Virginia, "The Evaluation of Perampanel as a Neuroprotective Pharmacotherapy in Traumatic Brain Injury" (2017). All ETDs from UAB. 973.
https://digitalcommons.library.uab.edu/etd-collection/973
